Free Trial
OTCMKTS:ATRX

Adhera Therapeutics (ATRX) Stock Price, News & Analysis

Adhera Therapeutics logo

About Adhera Therapeutics Stock (OTCMKTS:ATRX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$1 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ATRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATRX Stock News Headlines

Adhera Therapeutics Inc.
Adhera Therapeutics Inc (ATRX)
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
ATRX Adhera Therapeutics, Inc.
Adhera Therapeutics, Inc. (ATRX)
CGTX Cognition Therapeutics, Inc.
See More Headlines

ATRX Stock Analysis - Frequently Asked Questions

Adhera Therapeutics's stock reverse split before market open on Thursday, October 6th 2022.The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adhera Therapeutics investors own include Ashford Hospitality Trust (AHT), Peabody Energy (BTU), PlayAGS (AGS), Assertio (ASRT), Astronics (ATRO),

Company Calendar

Today
5/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ATRX
CIK
737207
Employees
2
Year Founded
1983

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
11,627,000
Free Float
8,348,000
Market Cap
$1 thousand
Optionable
Not Optionable
Beta
12.38
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (OTCMKTS:ATRX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners